K. Magiera-Mularz

发表

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

Katarzyna Guzik, A. Dömling, T. Holak, 2018, Expert opinion on therapeutic patents.

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Zefeng Wang, T. Holak, L. Skalniak, 2022, Molecules.

Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe

G. Dubin, T. Holak, K. Magiera-Mularz, 2022, Pharmaceuticals.

Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments

T. Holak, B. Musielak, K. Magiera-Mularz, 2022, ACS chemical biology.

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction

T. Holak, L. Skalniak, B. Musielak, 2021, Journal of medicinal chemistry.

Design, synthesis, evaluation and structural studies of C2-symmetric small molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) protein-protein interaction.

T. Holak, L. Skalniak, B. Musielak, 2019, Journal of medicinal chemistry.

Identification of small-molecule inhibitors of USP2a.

L. Skalniak, B. Musielak, Marcin D Tomala, 2018, European journal of medicinal chemistry.

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

A. Dömling, T. Holak, K. Magiera-Mularz, 2018, Angewandte Chemie.

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

L. Skalniak, K. Zak, B. Musielak, 2017, Angewandte Chemie.

Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists

B. Musielak, A. Dömling, T. Holak, 2021, ACS medicinal chemistry letters.

Human and mouse PD-L1: similar molecular structure, but different druggability profiles

L. Skalniak, B. Musielak, J. Kocik, 2020, iScience.

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

T. Holak, L. Skalniak, B. Musielak, 2020, Journal of medicinal chemistry.

Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions

T. Holak, B. Musielak, K. Magiera-Mularz, 2020, bioRxiv.

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action

T. Holak, L. Skalniak, B. Musielak, 2021, International journal of molecular sciences.

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?

T. Holak, L. Skalniak, B. Musielak, 2019, bioRxiv.

Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint

L. Skalniak, B. Musielak, J. Kocik, 2020 .

Death-Ligand 1 Protein−Protein Interaction

Lukasz, T. Holak, J. Kocik, 2021 .

Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein

T. Holak, A. Dömling, K. Magiera-Mularz, 2022, Molecules.

Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode.

T. Holak, Katarzyna Guzik, G. Dubin, 2021, Bioelectrochemistry.

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors

Constantinos G. Neochoritis, L. Skalniak, B. Musielak, 2023, Journal of medicinal chemistry.

Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.

B. Musielak, K. Magiera-Mularz, Yanling Wu, 2023, Journal of medicinal chemistry.

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

K. Magiera-Mularz, K. Węgrzyn, E. Sikorska, 2024, Translational oncology.

An updated patent review on PD-1/PD-L1 antagonists (2022-present).

L. Skalniak, K. Magiera-Mularz, Radosław Kitel, 2024, Expert opinion on therapeutic patents.